Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of REGN2176-3 in Wet AMD
NCT02061865Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2014
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rinucumab in exudative macular degeneration, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Safety. Started Feb 2014; status: completed.
02
Drugs
rinucumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02061865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061865.